Jennison Associates
CYTK icon

Jennison Associates’s Cytokinetics CYTK Stock Holding History

Jennison Associates’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-250,000
Closed -$2.38M – 722
2014
Q1 		$2.38M Buy
+250,000
New +$2.26M ﹤0.01% 573

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Jennison Associates's CYTK Position: Q2 2025 in Review

Jennison Associates sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 673,932 shares — an estimated $27.1M sold.

Jennison Associates first reported a position in CYTK in Q1 2014 and held it in 7 quarters. The position peaked at $27.1M in Q1 2025. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

  • Jennison Associates reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
  • Jennison Associates sold 673,932 Cytokinetics shares in Q2 2025, an estimated $27.1M.
  • Jennison Associates first reported a position in Cytokinetics in Q1 2014 and held it in 7 quarters.
  • Jennison Associates's Cytokinetics position peaked at $27.1M in Q1 2025.
  • 311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.